188P - The efficacy of neoadjuvant chemotherapy in patients with advanced colon cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer agents
Colon and Rectal Cancer
Surgical Oncology
Presenter Yao Lv
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors Y. Lv, G. Dai
  • Medical Oncology Department 2, Pla General Hospital, Military General Hospital of Beijing (PLA), 100853 - Beijing/CN

Abstract

Background

This study aimed to investigate the efficacy studies of neoadjuvant chemotherapy in patients with advanced colon cancer.

Methods

160 colon cancer patients were randomly assigned to an adjuvant chemotherapy group (n = 80) or a control group (n = 80) from January 2011-June 2015. The preoperative chemotherapy group were treated with FOLFOX chemotherapy for 4 cycles. The preoperative chemotherapy group underwent radical surgery after chemotherapy ended on 21d. The control group underwent radical surgery which did not work. Two groups were treated postoperatively with 4 cycles of chemotherapy. The treatment effect of two groups were compared.

Results

The staging grade of the preoperative chemotherapy group were lower than the control group (P  0.05). The excision rate of the adjuvant chemotherapy group was higher than the control groups (P 

Conclusions

Preoperative neoadjuvant chemotherapy in patients with advanced colon cancer can improve the resection rate and long-term survival and reduce the recurrence rate.

Clinical trial indentification

Legal entity responsible for the study

Medical Oncology Department 2, PLA General Hospital

Funding

Medical Oncology Department 2, PLA General Hospital

Disclosure

All authors have declared no conflicts of interest.